Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy.
immunotherapy
microenvironment
pancreatic cancer
prediction
tertiary lymphoid structure
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
15
05
2023
accepted:
26
06
2023
medline:
3
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Pancreatic cancer (PC) is extremely malignant and shows limited response to available immunotherapies due to the hypoxic and immunosuppressive nature of its tumor microenvironment (TME). The aggregation of immune cells (B cells, T cells, dendritic cells, etc.), which is induced in various chronic inflammatory settings such as infection, inflammation, and tumors, is known as the tertiary lymphoid structure (TLS). Several studies have shown that TLSs can be found in both intra- and peritumor tissues of PC. The role of TLSs in peritumor tissues in tumors remains unclear, though intratumoral TLSs are known to play an active role in a variety of tumors, including PC. The formation of intratumoral TLSs in PC is associated with a good prognosis. In addition, TLSs can be used as an indicator to assess the effectiveness of treatment. Targeted induction of TLS formation may become a new avenue of immunotherapy for PC. This review summarizes the formation, characteristics, relevant clinical outcomes, and clinical applications of TLSs in the pancreatic TME. We aim to provide new ideas for future immunotherapy of PC.
Identifiants
pubmed: 37529035
doi: 10.3389/fimmu.2023.1222719
pmc: PMC10388371
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1222719Informations de copyright
Copyright © 2023 Zou, Guan, Gao, Shi, Cui and Zhong.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2022 Jan 13;12:788640
pubmed: 35095864
PLoS One. 2017 Sep 21;12(9):e0185110
pubmed: 28934283
World J Gastroenterol. 2022 Mar 21;28(11):1088-1101
pubmed: 35431504
Front Immunol. 2018 May 14;9:1044
pubmed: 29868007
Cancer Discov. 2016 Mar;6(3):256-69
pubmed: 26715642
Trends Immunol. 2016 Jan;37(1):1-2
pubmed: 26706045
Methods Mol Biol. 2018;1845:71-86
pubmed: 30141008
Eur J Cancer. 2020 Jun;132:71-84
pubmed: 32334338
Cytokine. 2021 Oct;146:155650
pubmed: 34343865
Immunohorizons. 2020 Nov 5;4(11):688-700
pubmed: 33154038
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33055204
Cancer Immunol Immunother. 2018 Feb;67(2):195-207
pubmed: 29043413
Cancers (Basel). 2023 Jan 05;15(2):
pubmed: 36672316
Pancreas. 2014 Apr;43(3):470-7
pubmed: 24622082
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):
pubmed: 34261794
Front Immunol. 2022 Sep 16;13:962056
pubmed: 36189233
Pathology. 2016 Feb;48(2):177-87
pubmed: 27020390
Transplantation. 2008 Feb 15;85(3):309-11
pubmed: 18301324
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
Histopathology. 2021 Aug;79(2):200-209
pubmed: 33590538
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Oncoimmunology. 2021 Mar 17;10(1):1900635
pubmed: 33796412
Biochim Biophys Acta. 2016 Apr;1865(2):123-32
pubmed: 26794394
Expert Rev Anticancer Ther. 2018 Feb;18(2):131-148
pubmed: 29254387
Histopathology. 2019 Apr;74(5):709-717
pubmed: 30515871
Sci Transl Med. 2017 Apr 12;9(385):
pubmed: 28404866
J Leukoc Biol. 2018 Aug;104(2):333-341
pubmed: 29947426
Clin Cancer Res. 2022 Jan 1;28(1):150-162
pubmed: 34862242
Gastroenterology. 2012 Nov;143(5):1361-1374
pubmed: 22863765
Cancer Cell. 2014 May 12;25(5):621-37
pubmed: 24823639
Front Immunol. 2019 Apr 24;10:847
pubmed: 31068935
Cell. 2012 Jul 6;150(1):194-206
pubmed: 22770220
J Immunother Cancer. 2019 Aug 22;7(1):224
pubmed: 31439034
Am J Transplant. 2007 May;7(5):1071-9
pubmed: 17359505
J Immunol. 2018 Jan 15;200(2):432-442
pubmed: 29311385
Cancer Immunol Res. 2020 Mar;8(3):282-291
pubmed: 31871120
Int Rev Cell Mol Biol. 2018;341:63-124
pubmed: 30262035
Cancer Immunol Res. 2017 Nov;5(11):978-991
pubmed: 29066497
Neuroendocrinology. 2022;112(4):370-383
pubmed: 34157710
Immunity. 2022 Jan 11;55(1):115-128.e9
pubmed: 35021053
Oncoimmunology. 2016 Oct 7;5(12):e1240859
pubmed: 28123878
EBioMedicine. 2018 Dec;38:79-88
pubmed: 30497977
PLoS One. 2014 Mar 17;9(3):e91551
pubmed: 24637664
Oncoimmunology. 2017 Apr 28;6(6):e1322238
pubmed: 28680760
Cancer Cell. 2023 Jan 9;41(1):226
pubmed: 36626867
Trends Immunol. 2022 Apr;43(4):274-276
pubmed: 35272934
Cytotherapy. 2021 Feb;23(2):137-145
pubmed: 32907781
Am J Pathol. 2015 Jul;185(7):1935-43
pubmed: 25963989
Nat Rev Immunol. 2022 Apr;22(4):251-265
pubmed: 34389841
Cancer Discov. 2016 Mar;6(3):270-85
pubmed: 26715645
Signal Transduct Target Ther. 2020 Apr 17;5(1):38
pubmed: 32300119
J Exp Med. 2020 Aug 3;217(8):
pubmed: 32491160
Cancer Lett. 2020 Mar 1;472:8-18
pubmed: 31857154
J Immunol. 1986 Apr 1;136(7):2348-57
pubmed: 2419430
J Exp Med. 2019 Mar 4;216(3):621-637
pubmed: 30723095
Virchows Arch. 2021 Feb;478(2):209-217
pubmed: 32676968
Front Pharmacol. 2021 Nov 26;12:771046
pubmed: 34899325
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Cancer Lett. 2020 Feb 1;470:126-133
pubmed: 31730903
Nat Rev Immunol. 2014 Jul;14(7):447-62
pubmed: 24948366
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
Cancer Immunol Res. 2023 Apr 3;11(4):435-449
pubmed: 36689623
Nat Commun. 2021 Oct 18;12(1):6068
pubmed: 34663810
J Exp Med. 1996 Apr 1;183(4):1461-72
pubmed: 8666904
Oncoimmunology. 2021 Mar 29;10(1):1900508
pubmed: 33854820
J Immunol. 2002 Jul 1;169(1):424-33
pubmed: 12077273
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Gut. 2018 Sep;67(9):1663-1673
pubmed: 28774888
Cancers (Basel). 2023 Jan 29;15(3):
pubmed: 36765788
Front Immunol. 2022 Jun 29;13:870458
pubmed: 35844587
Prog Lipid Res. 2020 Nov;80:101055
pubmed: 32791170
Front Oncol. 2018 Sep 19;8:384
pubmed: 30283732
Pancreas. 2004 Jan;28(1):e26-31
pubmed: 14707745
Exp Dermatol. 2017 May;26(5):402-408
pubmed: 27673278
Cancer Immunol Res. 2014 Jul;2(7):616-31
pubmed: 24942756
Mol Cancer. 2018 Jul 30;17(1):108
pubmed: 30060755
Annu Rev Physiol. 2013;75:225-40
pubmed: 23043248
World J Surg Oncol. 2021 Oct 16;19(1):300
pubmed: 34654443
World J Gastroenterol. 2016 Mar 7;22(9):2678-700
pubmed: 26973408
Cancers (Basel). 2022 Dec 02;14(23):
pubmed: 36497450
Cancers (Basel). 2021 Jul 22;13(15):
pubmed: 34359579
Gastroenterology. 2018 Jul;155(1):210-223.e3
pubmed: 29604293
Front Immunol. 2021 May 26;12:648812
pubmed: 34122408
Immunity. 2021 Dec 14;54(12):2812-2824.e4
pubmed: 34861182
Immunity. 2000 May;12(5):471-81
pubmed: 10843380
Cells. 2021 Apr 22;10(5):
pubmed: 33922052
Front Immunol. 2012 Nov 30;3:350
pubmed: 23230435
Oncoimmunology. 2012 Nov 1;1(8):1323-1343
pubmed: 23243596
Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5026-31
pubmed: 17360402
Nat Rev Immunol. 2018 Feb;18(2):121-133
pubmed: 29082915
PLoS One. 2021 Sep 23;16(9):e0256907
pubmed: 34555057
Immunity. 2013 Jul 25;39(1):11-26
pubmed: 23890060
Cell Mol Gastroenterol Hepatol. 2021;12(5):1543-1565
pubmed: 34252585
Cancer Immunol Res. 2018 Jun;6(6):645-657
pubmed: 29653981
J Gastroenterol. 2023 Mar;58(3):277-291
pubmed: 36705749
Immunol Rev. 2023 May;315(1):71-78
pubmed: 36705244
J Clin Invest. 2021 Oct 1;131(19):
pubmed: 34411002
Oncoimmunology. 2020 Feb 17;9(1):1724763
pubmed: 32117589
Cancer Res. 2018 Mar 1;78(5):1308-1320
pubmed: 29279354
Immunol Rev. 2016 May;271(1):260-75
pubmed: 27088920
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
J Clin Med. 2021 Jan 30;10(3):
pubmed: 33573277
J Clin Invest. 1999 Mar;103(6):779-88
pubmed: 10079098
Science. 2022 Jan 07;375(6576):eabf9419
pubmed: 34990248
Cancer Sci. 2019 Jun;110(6):1853-1862
pubmed: 30997706
World J Gastroenterol. 2018 Nov 21;24(43):4846-4861
pubmed: 30487695
Int J Cancer. 2020 Jun 15;146(12):3461-3473
pubmed: 32129882
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Clin Cancer Res. 2019 Sep 1;25(17):5351-5363
pubmed: 31186314
Blood. 1998 Feb 15;91(4):1355-61
pubmed: 9454766
Front Immunol. 2020 Sep 10;11:2105
pubmed: 33013886
Cancer Biol Med. 2021 Sep 24;:
pubmed: 34553849
Br J Cancer. 2013 Mar 5;108(4):914-23
pubmed: 23385730
Oncoimmunology. 2022 Jan 31;11(1):2027148
pubmed: 35127251
J Cell Mol Med. 2022 Apr;26(7):1955-1968
pubmed: 35174623
Front Oncol. 2018 Jul 09;8:256
pubmed: 30038899
J Immunol. 2010 Sep 15;185(6):3359-68
pubmed: 20713891
Clin Sci (Lond). 2016 Feb;130(4):247-58
pubmed: 26590104
Cytokine Growth Factor Rev. 2014 Apr;25(2):125-37
pubmed: 24508087
Curr Opin Immunol. 2001 Feb;13(1):45-51
pubmed: 11154916
Cancer Res. 2020 May 15;80(10):1991-2003
pubmed: 32098780
Virchows Arch. 2021 Jun;478(6):1209-1214
pubmed: 32833039
PLoS One. 2014 May 01;9(5):e95986
pubmed: 24788814
Cancer Discov. 2016 Mar;6(3):247-55
pubmed: 26715643
Elife. 2020 May 05;9:
pubmed: 32367803
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Br J Cancer. 2017 Aug 8;117(4):451-460
pubmed: 28704840
Acad Radiol. 2022 Sep;29(9):e167-e177
pubmed: 34922828
Cancer Biol Ther. 2015;16(7):1099-109
pubmed: 25955104
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Nat Immunol. 2017 Nov;18(11):1207-1217
pubmed: 28892469
Nat Rev Immunol. 2010 Sep;10(9):664-74
pubmed: 20706277
Ann Rheum Dis. 2020 Dec;79(12):1588-1599
pubmed: 32963045
Kidney Int. 2017 Feb;91(2):375-386
pubmed: 27745702
Arthritis Rheumatol. 2020 Sep;72(9):1559-1570
pubmed: 32307922
Cancer Cell. 2023 Mar 13;41(3):527-545
pubmed: 36827979
Br J Cancer. 2015 May 26;112(11):1782-90
pubmed: 25942397
Aging (Albany NY). 2020 Jan 8;12(1):502-517
pubmed: 31913856